Letter by Putot et al Regarding Article, “Biomarkers Enhance Discrimination and Prognosis of Type 2 Myocardial Infarction”
- 23 February 2021
- journal article
- letter
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of the American College of Cardiology
- Vol. 143 (8), e250-e251
- https://doi.org/10.1161/circulationaha.120.051103
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- Biomarkers Enhance Discrimination and Prognosis of Type 2 Myocardial InfarctionJournal of the American College of Cardiology, 2020
- Type 1 or Type 2 Myocardial Infarction in Patients with a History of Coronary Artery Disease: Data from the Emergency DepartmentJournal of Clinical Medicine, 2019
- Differentiating type 1 and 2 acute myocardial infarctions using the N-terminal pro B-type natriuretic peptide/cardiac troponin T ratioThe American Journal of Emergency Medicine, 2018
- Discrimination of patients with type 2 myocardial infarctionEuropean Heart Journal, 2017
- Cardiac troponin changes to distinguish type 1 and type 2 myocardial infarction and 180-day mortality riskEuropean Heart Journal Acute Cardiovascular Care, 2014